CLOs on the Move

HemoShear Therapeutics

www.hemoshear.com

 
We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.hemoshear.com
  • 501 Locust Ave Suite 301
    Charlottesville, VA USA 22902
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Color

Color`s mission is to help people lead the healthiest lives that science and medicine can offer. We launched in April 2015 with a simple, affordable genetic test to help people understand their risk for hereditary cancer. In 2017, we added coverage for hereditary heart conditions.

Alta Biomedical Group

Alta Biomedical Group is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

K-LaB Technologies

K-LaB Technologies, Inc. is a Dripping Springs, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

eRAD

eRAD offers a complete suite of workflow solutions for the imaging industry. Its Meaningful Use-ready RIS, web-based PACS, and multi-site workflow solutions are used by teleradiology businesses, specialty reading groups, multi-site reading groups, hospitals and outpatient imaging centers. With over 300 customers in the US and several other countries, eRAD`s solutions are available as cloud-based hosted solutions, or as in-house enterprise solutions.

Senti Bio

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.